Charlotte T. Close
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Charlotte T. Close has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- A. Whitney Brown
Cystic Fibrosis Foundation, Bethesda, MD, USA
1 shared publication - Alyssa Dews
Genetic Counseling Graduate Program, Department of Human Genetics University of Michigan Medical School Ann Arbor Michigan USA
1 shared publication - Danielle Marie Goetz
University at Buffalo School of Medicine Buffalo New York USA
1 shared publication - Eden R. Brush
Program in Genetic Counseling Columbia University Vagelos College of Physicians and Surgeons New York New York USA
1 shared publication - Ketki Naik
Division of Clinical Genetics, Department of Pediatrics Columbia University Vagelos College of Physicians and Surgeons New York New York USA
1 shared publication - Luis de Jesus Gonzalez
Departments of Outpatient Pharmacy and Internal Medicine, University of New Mexico Hospitals, Albuquerque, NM, USA
1 shared publication
Latest Publications
- 29 January 2026
- Published by Wiley in Journal of Genetic Counseling
- Vol. 35 (1) , e70173
Assessing patient communication preferences for reclassified variants of uncertain significance in a general genetics clinic
Increased detection of variants of uncertain significance (VUS) from clinical genomic testing has brought about more frequent variant reclassifications which have the potential to impact patient care and well‐being. However, the lack of best practice guidelines on communicating reclassified results to patients and limited genetic counselor (GC) bandwidth has led to inconsistent disclosure practices and potential inequities in patient care. This cross‐sectional study aimed to capture patient preferences for communication of VUS reclassifications. We surveyed 224 adult patients and parents/primary caregivers of pediatric patients with a VUS result from a general genetics clinic. The online survey included questions on preferred disclosure methods for VUS results downgraded to (likely) benign (dVUS) versus upgraded to (likely) pathogenic (uVUS), and perceived benefits of these methods. For dVUS, the largest group of participants preferred written disclosure (52.7%) with email being the most favored modality (71.4%). However, those with a non‐English primary language and lower education preferred verbal disclosure ( p = 0.015 and p = 0.005 respectively). For uVUS, the largest proportion of participants (51.3%) preferred a sequential combination of written followed by verbal disclosure, with phone call (72.3%) and email (70.5%) being the preferred verbal and written modalities, respectively. Participants favored a verbal disclosure component for uVUS more than for dVUS ( p = 0.002). Perceived benefits of a written disclosure included providing documentation (71.4%) and clarity of information (70.5%) while the primary benefit of verbal disclosure was the ability to ask questions (82.7%). Overall, most patients found written disclosure sufficient for dVUS and preferred a sequential combination of written followed by verbal disclosure for uVUS, suggesting a need to process information before speaking with a clinician. This study offers patient‐driven insights on optimizing communication methods for VUS reclassification disclosures, aiming to minimize GC burden and patient care disparities.
- 29 January 2026
- Published by Wiley in Journal of Genetic Counseling
- Vol. 35 (1) , e70173
Assessing patient communication preferences for reclassified variants of uncertain significance in a general genetics clinic
Increased detection of variants of uncertain significance (VUS) from clinical genomic testing has brought about more frequent variant reclassifications which have the potential to impact patient care and well‐being. However, the lack of best practice guidelines on communicating reclassified results to patients and limited genetic counselor (GC) bandwidth has led to inconsistent disclosure practices and potential inequities in patient care. This cross‐sectional study aimed to capture patient preferences for communication of VUS reclassifications. We surveyed 224 adult patients and parents/primary caregivers of pediatric patients with a VUS result from a general genetics clinic. The online survey included questions on preferred disclosure methods for VUS results downgraded to (likely) benign (dVUS) versus upgraded to (likely) pathogenic (uVUS), and perceived benefits of these methods. For dVUS, the largest group of participants preferred written disclosure (52.7%) with email being the most favored modality (71.4%). However, those with a non‐English primary language and lower education preferred verbal disclosure ( p = 0.015 and p = 0.005 respectively). For uVUS, the largest proportion of participants (51.3%) preferred a sequential combination of written followed by verbal disclosure, with phone call (72.3%) and email (70.5%) being the preferred verbal and written modalities, respectively. Participants favored a verbal disclosure component for uVUS more than for dVUS ( p = 0.002). Perceived benefits of a written disclosure included providing documentation (71.4%) and clarity of information (70.5%) while the primary benefit of verbal disclosure was the ability to ask questions (82.7%). Overall, most patients found written disclosure sufficient for dVUS and preferred a sequential combination of written followed by verbal disclosure for uVUS, suggesting a need to process information before speaking with a clinician. This study offers patient‐driven insights on optimizing communication methods for VUS reclassification disclosures, aiming to minimize GC burden and patient care disparities.
- Open Access
- 25 September 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (6) , 1045-1054
Cystic fibrosis foundation position paper: Redefining the cystic fibrosis care team
- 25 September 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (6) , 1045-1054
Open AccessCystic fibrosis foundation position paper: Redefining the cystic fibrosis care team